Marker therapeutics, inc. (MRKR)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current assets:
Cash and cash equivalents

40,255

43,903

48,477

53,444

57,706

61,746

-

-

-

5,129

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash

-

-

-

-

-

-

4,294

7,782

2,801

-

7,607

9,962

5,927

7,851

9,586

3,767

5,721

6,576

6,087

3,105

1,453

141

613

20

93

48

4

4

33

3

12

23

250

34

14

23

Due from government agency

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

1

1

1

1

1

Prepaid expenses and deposits

1,716

1,526

1,906

491

216

141

96

108

129

51

96

179

177

70

111

21

37

68

-

-

-

-

30

15

-

15

-

-

-

-

-

-

-

-

-

-

Interest receivable

24

56

78

98

112

108

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest receivable

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

13

-

-

-

-

-

-

-

-

-

-

Deferred financing costs (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

-

32

-

-

-

Total current assets

41,995

45,486

50,461

54,034

58,035

61,996

4,391

7,891

2,930

5,180

7,704

10,141

6,105

7,921

-

3,789

5,759

-

6,225

3,247

-

-

643

35

-

77

-

151

-

39

39

66

340

60

52

25

Non-current assets:
Property, plant and equipment, net

482

417

438

413

360

147

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets, net

407

455

501

547

592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total non-current assets

889

872

940

960

952

147

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due from government agency

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

1

-

-

-

-

-

-

-

Prepaid expenses and deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

138

142

82

82

-

-

15

-

118

118

15

-

-

-

-

-

-

-

Prepaid expenses and deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26

41

56

25

36

0

Prepaid expenses and deposits (Note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22

-

-

-

-

-

-

Deferred financing costs (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

25

26

37

12

24

28

0

36

40

91

Total assets

42,885

46,359

51,402

54,995

58,987

62,144

4,391

7,891

2,930

5,180

7,704

10,141

6,105

7,921

9,698

-

-

6,645

-

-

1,536

224

-

-

109

-

150

151

87

60

64

94

307

97

92

116

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities

2,955

1,757

2,858

2,946

2,694

2,754

3,588

3,595

2,301

1,513

1,757

1,561

1,449

1,224

1,678

1,346

1,454

967

-

-

-

-

671

1,212

-

3,778

-

-

-

-

1,048

701

794

1,025

711

809

Lease liability

209

204

199

194

189

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

874

842

703

693

-

-

3,865

-

1,457

1,898

1,941

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,327

-

-

-

-

-

-

Research agreement obligations

-

-

-

-

-

-

-

-

-

-

0

0

492

492

492

492

492

492

492

492

492

492

-

-

492

-

492

443

415

365

321

303

259

220

206

141

Derivative liability  conversion option (Note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

-

195

329

867

200

-

-

0

-

-

-

Warrant liability

0

31

129

65

58

49

107

147

8

9

6

10

17

14

29

21,252

29,489

26,493

32,196

69,962

8,994

9

-

-

603

-

89

462

977

-

894

1,246

-

-

-

-

Promissory note

-

-

-

-

-

-

5

5

5

-

5

5

5

5

5

5

5

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

23

23

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

52

52

52

52

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research agreement obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-492

-492

-

-492

-

-

-

-

-

-

-

-

-

-

Derivative liability - conversion option

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-582

-

-

-

-

-

-

-

-

-

-

Derivative liability - warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

140

-

-

-

-

-

-

-

-

-

-

Derivative liability  warrants (Note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

871

-

-

-

-

-

-

Derivative liability  warrants (Note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,317

-

-

-

Convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

434

3,161

2,348

2,064

1,476

1,184

1,097

1,048

998

-

-

353

Derivative liability - warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

83

298

-

-

-

-

-

-

-

-

-

-

-

-

Convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

356

-

-

-

-

-

-

-

-

-

-

-

-

Loans payable, related party (2013 - $5,200)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

18

-

42

-

-

-

-

-

-

-

-

-

-

Promissory note, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-52

-67

-

-277

-

-

-

-

-

-

-

-

-

-

Loans payable (Note 6)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18

-

10

10

10

28

25

7

7

7

7

425

Promissory notes (Note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

-

277

277

67

-

-

-

-

-

-

-

Promissory note (Note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

167

152

100

100

100

100

-

Due to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

81

369

381

153

373

281

220

293

322

303

251

259

Due to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-152

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

3,164

1,992

3,187

3,206

2,941

2,803

3,700

3,747

2,314

1,522

1,768

1,576

1,964

1,736

2,204

23,118

31,464

28,005

33,615

71,349

10,243

1,248

1,299

2,598

5,614

8,845

5,252

5,640

6,129

4,428

3,760

3,700

3,800

1,705

1,370

3,983

Non-current liabilities:
Lease liability, net of current portion

226

280

333

385

435

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total non-current liabilities

226

280

333

385

435

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible notes payable (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

568

504

-

Total liabilities

3,390

2,273

3,520

3,591

3,377

2,803

3,700

3,747

2,314

1,522

1,768

1,576

1,964

1,736

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,273

1,874

-

Commitments and contingencies (see Note 9)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

-

0

0

-

-

-

-

-

-

-

0

-

-

-

-

0

0

-

-

-

0

Stockholders' equity:
Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized: Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of September 30, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock, $0.001 par value, 150 million shares authorized, 46.5 million and 45.7 million shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

46

45

45

45

45

45

13

13

10

10

10

10

8

8

8

71

70

5

62

38

32

20

19

160

159

1

142

85

76

73

72

54

52

47

46

40

Additional paid-in capital

373,467

371,573

370,290

368,353

366,989

365,400

171,221

170,287

161,221

161,067

160,662

159,306

152,368

151,991

151,724

112,882

112,482

112,142

104,402

92,218

85,269

85,265

84,484

81,222

78,895

46,715

46,381

44,456

43,483

-

-

-

-

-

-

-

Accumulated deficit

-334,019

-327,533

-322,454

-316,994

-311,424

-306,105

-170,545

-166,156

-160,616

-157,420

-154,736

-150,751

-148,235

-145,815

-144,238

-132,284

-138,258

-133,508

-131,855

-160,359

-94,009

-86,309

-55

-

-

-55,426

-

-

-

-

-

-

-

-

-

-

Shares to be issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

468

493

633

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-85,573

-58

-

-58

-

-

-

-

-

-

-

-

-

-

Shares to be issued (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

352

-

-

-

-

-

-

-

Shares and warrants to be issued (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

384

367

-

-

137

413

362

350

112

34

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,220

43,019

40,334

39,943

43,451

30,927

37,812

Shares and warrants to be issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

242

-

-

-

-

-

-

Subscriptions receivable (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

-

-

-

-

Deferred compensation (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

35

86

142

-

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

84,380

85,133

-

51,950

50,335

49,894

47,840

46,865

44,320

43,722

45,879

32,665

41,693

Accumulated other comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-59

-

-59

-63

-61

-63

-60

-62

-60

-58

-62

-60

Total stockholders' equity

39,495

44,086

47,881

51,403

55,610

59,340

690

4,144

615

3,658

5,936

8,565

4,141

6,184

7,493

-19,329

-25,704

-21,360

-27,390

-68,102

-8,707

-1,023

-656

-2,562

-5,505

-8,768

-5,102

-5,488

-6,042

-4,367

-3,696

-3,605

-3,460

-2,176

-1,782

-3,866

Total liabilities and stockholders' equity

42,885

46,359

51,402

54,995

58,987

62,144

4,391

7,891

2,930

5,180

7,704

10,141

6,105

7,921

9,698

3,789

5,759

6,645

6,225

3,247

1,536

224

643

35

109

77

150

151

87

60

64

94

340

97

92

116

Series A Preferred Stock [Member]
Preferred Stock, Value

-

-

-

-

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B Preferred Stock [Member]
Preferred Stock, Value

-

-

-

-

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-